Summit Therapeutics Inc stock is traded at $14.15, with a volume of 5,484,725. It is down -6.14% in the last 24 hours and down -8.83% over the past month. Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Previous Close:
$15.08
Open:
$15.20
24h Volume:
5,484,725
Relative Volume:
1.08
Market Cap:
$11.32B
Revenue:
$220.00K
Net Income/Loss:
-$1.21B
P/E Ratio:
-
EPS:
-$1.60
Net Cash Flow:
-$387.48M
1W Performance:
-13.35%
1M Performance:
-8.83%
6M Performance:
-24.69%
1Y Performance:
-22.51%
1-Day Range:
$14.06$15.20
1-Week Range:
$14.06$18.15
52-Week Range:
$12.07$29.23
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
305-203-2034Address
601 BRICKELL KEY DRIVE, MIAMI, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS